Lupin gets tentative USFDA nod for sales of Nausea drug

Pharmaceutical major Lupin said that it received tentative approval from the United States Food and Drug Administration for the sales of a generic equivalent of Merck Sharp & Dohme Corp’s Emend Injection drug.

Fosaprepitant, 150 mg had annual sales of $312 million in the US market.

A tentative approval means that the company has to wait for all patent and other protections to expire before starting the sale of the drug.

Fosaprepitant injection is used for the treatment of nausea and vomiting caused by chemotherapy. It works by blocking one of the natural substances, neurokinin 1, that causes vomiting.

Mumbai-based Lupin is one of the world’s biggest makers of generic drugs, and sells both branded and generic formulations, biotechnology products and pharmaceutical ingredients globally.

It is the world’s biggest manufacturer of anti-TB medicines and focuses on cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID segments of the pharma market.